Skip to content

Study on the correlation between anti-rituximab antibody and the clinical efficacy of rituximab in the treatment of adult primary membranous nephropathy

Study on the correlation between anti-rituximab antibody and the clinical efficacy of rituximab in the treatment of adult primary membranous nephropathy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400093037
Enrollment
Unknown
Registered
2024-11-27
Start date
2024-02-05
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

idiopathic membranous nephropathy

Interventions

ARA positive group:NA
ARA negative group:NA

Sponsors

Shenzhen Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of pMN; 2. Over 18 years of age; 3. eGFR>40ml/min; 4. Use RTX to therapy.

Exclusion criteria

Exclusion criteria: 1.Patients with secondary MN; 2.Patients with lymphoma, SLE, RA, hepatitis B, hepatitis C, AIDS and other diseases; 3.Allergic to RTX or mouse protein; 4.Patients with severe active infection; 5.Patients with severely impaired immune response (such as hypogammaglobulinemia, severe decreased CD4 or CD8 cell counts); 6.Patients with severe heart failure (NYHA grade ?); 7.Use of Glucocorticoid, CNI or cyclophosphamide within 4 months; 8.Pregnant and breastfeeding.

Design outcomes

Primary

MeasureTime frame
urine protein;

Secondary

MeasureTime frame
renal function;adverse event;Anti-rituximab antibodies titer;Rituximab drug concentration;B lymphocyte count;Anti-PA2R antibody titer;Random urinary total protein creatinine ratio, UPCR;

Countries

China

Contacts

Public ContactQijun Wan

Shenzhen Second People's Hospital

yiyuan2224@sina.com+86 13537857368

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026